Immunothérapie des lymphomes diffus à grandes cellules B chimioréfractaires ou en rechute postautogreffe (notice n° 659630)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 03108cam a2200313 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250121191945.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Lemoine, Jean |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Immunothérapie des lymphomes diffus à grandes cellules B chimioréfractaires ou en rechute postautogreffe |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2021.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 32 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Le pronostic défavorable des lymphomes diffus à grandes cellules B (LDGCB) chimioréfractaires ou en rechute postautogreffe appelle au développement de stratégies thérapeutiques alternatives. En effet, si ces hémopathies sont caractérisées par leur haute chimiorésistance, une réponse antitumorale pourrait être obtenue de façon indirecte en favorisant l’éradication des cellules malignes par le système immunitaire. Dans ce contexte, de multiples immunothérapies sont développées pour la prise en charge des LDGCB réfractaires ou en rechute, telles que les immunoconjugués, les immunomodulateurs, les inhibiteurs de points de contrôle immunitaires, les anticorps bispécifiques ou encore les lymphocytes T modifiés pour exprimer un récepteur antigénique chimérique. Ces traitements ont permis d’obtenir des résultats remarquables, possiblement curatifs, et plusieurs d’entre eux ont déjà été approuvés par les autorités de santé. Ces immunothérapies devraient donc continuer de transformer la prise en charge des LDGCB en échec de chimiothérapie. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Given the poor prognosis of patients with relapsed or refractory diffuse large B-cell lymphomas (R/R LDGCB), the development of novel alternative strategies is necessary. In these highly chemoresistant diseases, antitumoral responses may be obtained by enabling the immune system to kill malignant cells in an indirect manner. The last decade has witnessed the emergence of novel forms of immunotherapy, including immunoconjugates, immunomodulatory drugs (IMiDS), immune checkpoint blockers, bispecific antibodies and chimeric antigen receptor T cells (CAR-T cells). These treatments have shown phenomenal successes, sometimes curative, compared to the results obtained with conventional approaches. These immunotherapies will likely transform the treatment paradigms for R/R LDGCB and that their earlier use in the therapeutic strategy may be addressed in patients at high-risk of chemoresistance. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | immunoconjugués |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | lymphocytes T modifiés pour exprimer un récepteur antigénique chimérique |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | inhibiteurs de points de contrôle immunitaires |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Lymphomes diffus à grandes cellules B |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | immunomodulateurs |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | immunoconjugates |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | immunomodulatory drugs |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | chimeric antigen receptor T cells |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | bispecific antibodies |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Diffuse large B-cell lymphomas |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | immune checkpoint blockers |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Houot, Roch |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Hématologie | 27 | N° Supp 1 | 2021-03-15 | p. 26-36 | 1264-7527 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-hematologie-2021-HS1-page-26?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-hematologie-2021-HS1-page-26?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux